For 2-year survivors, the COS3 and annual hazard of death were 88% and < 7% for NK/TCL, 78% and < 10% for angioimmunoblastic T-cell lymphoma (AITL), 94% and <1% for ALK+ALCL, 82% and 20% for ALK-ALCL, 60% and 31% for peripheral T-cell Lymphoma, not otherwise specified (PTCL, NOS), and 69% and 16.5% for other histological types (Others), respectively (Figure 2). This evidence concerns the gene ALK and anaplastic large cell lymphoma.